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surgical cosmesis were more likely to develop photographically as-
sessed breast shrinkage (OR 1.54, 95% CI 1.21-1.96; p<0.001), tumour 
bed induration (OR 1.80, 95% CI 1.43-2.26; p<0.001) and sub-optimal 
cosmesis (OR 8.15, 95% CI 6.08-10.92; p<0.001) at five years. 
Conclusions: Improved dose homogeneity with IMRT translates into 
superior overall cosmesis and reduces the risk of skin telengiectasia at 
5 years post RT. These results are practice-changing and should 
encourage other centres still using 2D standard RT to implement 
breast IMRT. In addition, surgical cosmesis should be optimised as this 
also has a significant effect on late breast toxicities. 
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Purpose/Objective: Radiation therapy (RT) significantly ameliorates 
local control in breast cancer (BC) patients treated with breast 
conserving surgery and in high relapse risk radically resected patients. 
Some debate exist about the value of RT in elderly patients. In this 
retrospective analysis on a single institution series of BC patients we 
evaluate local control as regard to age and different prognostic 
factors. 
Materials and Methods: Patients undergoing postoperative RT for 
localized breast cancer treated at our institution between January 
1999 and December 2008 were the object of the study. RT consisted 
of 50 Gy in 5 weeks on the chest wall, in the case of mastectomy, and 
on residual breast in the case of quadrantectomy or lumpectomy, and 
eventually on the axillar and supraclavear nodes. A boost of 10Gy was 
administered to the tumor bed of all the conserving surgery treated 
patients. The clinical data were analyzed with univariate and 
multivariate analysis considering age (<40, 40-64, ≥65), nodal status 
(N + vs N-), tumor classification (T1 vs >T1), grading (G1–2 vs G3), 
oestrogen and progesterone receptors (ER and PgR), and erb-B2 
status. A further classification of patients according to a surrogate 
approximate genetic signature and recognizing the four subtypes of 
BC, namely luminal A (ER + and/or PgR + , and erb-B2–), luminal B 
(ER+ and/or PgR + , and erb-B2 + ), HER-2 (ER-, PgR– and erb-B2 + ), 
and basal(ER–, PgR– and erb-B2–) was adopted. Freedom from loco-
regional relapse (FFLR) was defined as the time from diagnosis to the 
loco-regional relapse (LR). The 8-year LR rate was estimated by the 
Kaplan-Meier method. 
Results: Seven hundred thirty-three patients with a median age of 53 
years (range 27-84) and with a minimum follow up of 12 months 
entered the study. Chemotherapy, hormonal therapy or both, were 
administered at 57, 374, and 249 patients, respectively. The median 
follow up was 84 months (range 12 – 126), with an overall survival of 
96%. The 8-year actuarial rate of LR was 3%. Univariate analysis 
showed a significant relation of LR with age (LR=6.1% for age<40 
years, LR=1.6% for 40≤age<65, LR=6.5% forage ≥65), grading (LR=1.7% 
for G1–2, LR=4.1% for G3), ER status (LR=2.3% forER-, LR=5.4% for ER+) 
and HER2 subtype (LR=2.3% for no-HER2, LR=8.5% for HER2). From the 
multivariate analysis, age (hazard risk 3.9 for age≥65 years and 3.2for 
age<40 years compared with 40≤age<65) and HER2 subtype (hazard 
risk3.8) were the only significant factors for LR risk prediction (Fig.1). 
 
Figure 1 
 
  
Conclusions: Age less than 40 and equal to or more than 65 years and 
HER-2 subtype are associated with a greater risk of local relapse. 
These results do not support a different RT management of elderly 
patients.  
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Background: Although radiotherapy is a very cost-effective treatment 
modality, it requires major investments for building and equipment. 
Adequate planning of radiotherapy infrastructure and personnel may 
prevent waiting lists and overcapacity with vacancies. In the 
Netherlands, until recently, radiotherapy capacity was regulated by 
the government. Until 2000 this was done by a limitation of the 
number of linear accelerators and since then by a limitation of the 
number of centers. Models have been used to estimate the expected 
number of cancer patients, patients requiring radiotherapy and the 
distribution over different types of treatment (simple, standard, 
intensive, or special). This was used to determine the required 
number of machines and staffing. The actual situation in the 
Netherlands is evaluated annually by a survey of all Dutch centers. 
Materials and methods: For the period from 1998 to 2010, the 
predictions from the Dutch Society of Radiotherapy and Oncology 
were compared with the actual measures from annual surveys of the 
21 Dutch centers. In addition, developments of productivity and 
departments size are evaluated. 
Results: An annual increase in the number of patients and 
radiotherapy treatments of 3.5-4.0 % was observed. The number of 
machines and staffing increased accordingly. After a relative increase 
in the percentage of 3D conformal treatments in the late 1990s and 
early 2000s, a shift from 3D-conformal techniques to intensity 
modulated, image-guided and stereotactic techniques was seen in the 
later years. In 2010, 39% of the treatment series was delivered using 
IMRT, IGRT, SBRT or radiosurgery techniques, 21% using 3D-conformal 
techniques an 40% using standard techniques. In 1998, their were 274 
treatment series per radiation oncologist, 625 per physicist and 532 
per linear accelerator, compared to 249 series per radiation 
oncologist, 540 per physicist and 451 per accelerator in 2010.  
The number of radiotherapy departments did not increase over the 
study period. The average size of the centers was 5.7 accelerators, 
10.4 fte radiation oncologists, 4.8 fte clinical physicists and 45.8 fte 
technologists, compared to 3.2 accelerators and 6.2 fte, 2.7 fte and 
30.4 fte, respectively in 1998.  
Discussion: Prognoses of the number and types of radiotherapy 
treatments allow for an accurate prediction and planning of the 
required staffing and infrastructure to avoid waiting lists and 
overcapacity. The expansion of the existing departments instead of 
the addition of new centers, allows for a more rapid implementation 
of new techniques and will allow sufficient sub-specialization of the 
staff. In recent years, the expansion of departments is often realized 
by establishing ‘satellite centers’, which are an integral part of the 
main center. Treatment planning is performed at the main site and 
the staff rotates over the satellite(s) and the main center. 
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Historically, England has faced an under-provision of radiotherapy, 
due in part to the decentralised nature of equipment procurement 
and workforce management. The ESTRO QUARTS report showed that 
England operated just over 50% of the estimated number of 
megavoltage radiotherapy units estimated as necessary for treatment 
of cancer in the population. 
In 2007 the National Radiotherapy Advisory Group’s report was 
commissioned by Prof. Mike Richards, National Cancer Director. It 
suggested that a 63% increase was required to bridge the gap between 
actual radiotherapy activity (30,000 fractions per million/year) and 
optimum treatment levels(48,000 fractions per million/year). 
Projections of treatment activity suggested that by 2016, activity 
levels of 54,000 fractions per million/year would be required. The 
report recommended a long term strategy for the development and 
expansion of a multi-professional workforce for radiotherapy delivery, 
the expansion and modernisation of radiotherapy delivery services,the 
central collection of radiotherapy treatment statistics, and 
improvement in treatment quality starting with IMRT and moving over 
a decade to 4-D adaptive radiotherapy. A National Radiotherapy 
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Implementation Group (NRIG) was established to implement these 
recommendations. 
The NRAG model of radiotherapy demand was seen asoverambitious 
and unrealistic and the Malthus Programme was commissioned to 
review and update the work. Malthus is an academic initiative to 
provide adiscrete event tool for simulation of radiotherapy demand in 
the U.K. at alocal level. Launched in October 2011, the tool provides 
radiotherapy service managers and healthcare commissioners with a 
customisable tool that can quantify radiotherapy demand at the level 
of the primary care trust (mean population = 330,000) or cancer 
network (mean population = 2,300,000). Clinical decision making is 
encoded into disease specific decision trees, established by a review 
of current evidence based practice for radiotherapy. The tool uses 
curated data feeds from the national cancer intelligence network to 
provide accurate local population demographic and cancer incidence 
data. Models for population growth and change in cancer incidence 
are used to forecast radiotherapy demand through to 2030. The 
estimate of radiotherapy demand forthe U.K as a whole for 2016 is 
55,000 fractions per million, closely similar to that of NRAG. To 
encourage expansion of radiotherapy there is now a nationallyagreed 
tariff and the service will be commissioned nationally 
The Radiotherapy Dataset (RTDS) collates information on treatment 
activity via electronic feeds from all radiotherapy centres in England. 
Monthly data uploads have been mandatory since April 2009, and 
datafeeds from RTDS are available with a 12 month latency from the 
Cancer Commissioning Toolkit. These data can be compared to the 
Malthus model in order  to understand radiotherapy provision for the 
local population. As local data on stage and performance status 
become available it will be possible to assess the influence of these 
factors on the uptake of radiotherapy and whether or not they have a 
significant influence in addition to under-investment. 
IMRT delivery has increased from 2% of patients in 2008 to 11% of all 
patients in 2012. It is expected that IMRT will be offered to the 33% of 
radically treated patients who would benefit by the end of 2013. A 
national programme to support IMRT training, implementation, and 
quality assurance has been established to overcome the barriers 
including staff shortages, lack of agreed funding for IMRT, and low 
levels of training in IMRT implementation. The expansion of IGRT will 
then pave the way to the development of 4D adaptive radiotherapy as 
envisaged in the NRAG report of 2007. 
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Based on detailed evidence-based modeling, radiotherapy has been 
identified as a necessary component of the oncological treatment in 
on average 52% of allnewly diagnosed cancer patients. Such estimates 
are important to help forecast radiotherapy resource and personnel 
needs. But when applied to different countries, such as in the highly 
variable European context, one should be aware that they are sensi-
tive to the demographic and socio-economic factors in these countries 
and to changes in incidence, population mix and stage distribution 
over time. 
In the early years 2000, the ESTRO-QUARTS-project used a combina-
tion of epidemiology, evidence-based radiotherapy indications and 
resource use to evaluate the differences in needs amongst 23 Euro-
pean countries. Along with this modelling exercise, it also suggested 
benchmarks for infrastructure and personnel requirements. 
Although extremely valuable, these data only represented a snapshot 
in time. To be of practical help for the European countries to support 
their radiotherapy training programmes and infrastructure projec-
tion,they do not only need regular update and correction for the 
changing cancer incidence and demographics, they should also take 
the evolving evidence on radiotherapy indications, utilisation and 
complexity into account. Furthermore,there is an urgent need for 
accurate data on infrastructure and personnel availability, to put the 
estimated needs into the correct perspective.  
Hence, almost a decade later, ESTRO has launched the HERO-project 
(Health Economics in Radiation Oncology), of which the overall aim is 
to develop a knowledge base and a model for health economic evalua-
tion of radiation treatments at the European level.  
As a first task in the project, a validated and detailed blueprint of the 
present situation of radiotherapy in Europe is made in terms of cancer 
incidence, number of centres, equipment and personnel and of reim-
bursement. Furthermore, a refinement of the QUARTS analysis on the 
needs is carried out, based on modelling exercises incorporating the 
most recent evidence-based utilisation estimates of CCORE.  
Apart from supporting the European countries and national societies 
within radiotherapy and oncology in their strive for optimal radiothe-
rapy capacity planning, these data will be used to feed nation-based 
cost-accounting models for radiotherapy. Finally, these data will also 
form the basis for cost-effectiveness analyses to evaluate the value 
for money of radiotherapy innovations and of radiotherapy compared 
to other oncologic treatments. 
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Because of inevitable uncertainties in RT, margins assure that the 
prescribed dose is actually absorbed in the target. A major 
breakthrough in thinking about margins occurred with the appearance 
of ICRU50, standardizing terminology. Around the same time, random 
errors, that affect each treatment fraction differently, and systematic 
errors that affect all fractions in the same way were differentiated. A 
second breakthrough occurred in the second half of the nineties when 
it was realized that you have to make a trade-off between the risk of 
underdosing the target that reduces with bigger margins, versus the 
risk of overdosing normal tissues that increases with bigger margins. 
This trade-off is then expressed is the probability of a certain 
underdose of the target. Using then plausible uncertainty data for the 
prostate, it appeared that a 90% probability of delivering 95% of the 
prescribed dose in the target required a then routine 1 cm margin. 
I.e., these numbers were apparently clinically acceptable and they 
formed the basis for the (simplified) NKI margin recipe: M = 2.5 SIGMA 
+ 0.7 sigma. Many authors have challenged and refined this 
publication but it it is still being widely used. The equations works 
well for a wide range of situations and are safe if you adjust the 
SIGMA and sigma for the number of fractions given.  
Then what are the problems with margins? First, they do not take the 
beam and patient geometry into account. E.g., a high dose is assumed 
even where the margin overlap an organ at risk, while the probability 
of the target being in that location during treatment may be very 
small. Ad-hoc adjustments are therefore often made, but this makes 
it very difficult to assure robustness or even estimate the level of 
robustness of the modified plan. Finally, with painted dose 
distributions, no simple margins recipes exist. 
How are we going to deal with these problems? Well there is only one 
good solution, margins have to go! By incorporating the knowledge 
about residual uncertainty distributions directly into IMRT planning, 
robust dose distributions are sculpted that take the actual shape of 
the dose distribution and the location of organs at risk into account 
when generating a ‘margin’. A number of publications have 
investigated this approach, demonstrating the possibility to develop 
plans that are just as robust as their margin-based counterparts, but 
with much lower exposure of the organs at risk. The resulting plans 
look very sensible, e.g., similar to integrated boost approaches with 
reduced margins towards organs at risk but with guaranteed 
robustness. And why is not everybody using this approach if it is 
clearly better? This is because so far planning system vendors have 
refused to invest in this approach. Hopefully this situation will change 
soon. 
 
 
 
 
 
 
